Treating hepatocellular carcinoma with sorafenib in liver transplant patients: An initial experience

R. F. Saidi, S. A. Shah, A. P. Rawson, St Grossman, B. Piperdi, A. Bozorgzadeh

Research output: Contribution to journalArticle

17 Scopus citations


Sorafenib has been approved for the treatment of advanced hepatocellular carcinoma (HCC). However, there are no data reported on its use in HCC patients with localized disease who have undergone orthotopic liver transplantation (OLT). Herein, we have reviewed our initial experience with 7 HCC patients who were candidates for OLT and were treated with sorafenib. Treating liver transplant patients with sorafenib appeared to be safe based upon our limited experience. There is a strong need for clinical trials to comprehensively study the safety of sorafenib before OLT.

Original languageEnglish (US)
Pages (from-to)4582-4584
Number of pages3
JournalTransplantation proceedings
Issue number10
StatePublished - Dec 1 2010
Externally publishedYes


ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this